- Home
- HRMY vs ENLT Comparison
HRMY vs ENLT Comparison
Compare HRMY & ENLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- ENLT
- Stock Information
- Founded
- HRMY 2017
- ENLT 2008
- Country
- HRMY United States
- ENLT Israel
- Employees
- HRMY N/A
- ENLT N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- ENLT
- Sector
- HRMY Health Care
- ENLT
- Exchange
- HRMY Nasdaq
- ENLT Nasdaq
- Market Cap
- HRMY 2.1B
- ENLT 2.9B
- IPO Year
- HRMY 2020
- ENLT 2023
- Fundamental
- Price
- HRMY $32.05
- ENLT $28.96
- Analyst Decision
- HRMY Strong Buy
- ENLT Hold
- Analyst Count
- HRMY 9
- ENLT 3
- Target Price
- HRMY $55.33
- ENLT $24.00
- AVG Volume (30 Days)
- HRMY 662.4K
- ENLT 23.1K
- Earning Date
- HRMY 10-28-2025
- ENLT 11-12-2025
- Dividend Yield
- HRMY N/A
- ENLT N/A
- EPS Growth
- HRMY 58.41
- ENLT N/A
- EPS
- HRMY 3.10
- ENLT 0.17
- Revenue
- HRMY $772,527,000.00
- ENLT $428,715,000.00
- Revenue This Year
- HRMY $20.09
- ENLT $355.90
- Revenue Next Year
- HRMY $16.74
- ENLT $42.83
- P/E Ratio
- HRMY $10.50
- ENLT $170.89
- Revenue Growth
- HRMY 17.74
- ENLT 39.54
- 52 Week Low
- HRMY $26.47
- ENLT $14.01
- 52 Week High
- HRMY $41.61
- ENLT $29.84
- Technical
- Relative Strength Index (RSI)
- HRMY 29.50
- ENLT 61.10
- Support Level
- HRMY $31.61
- ENLT $28.23
- Resistance Level
- HRMY $37.05
- ENLT $29.84
- Average True Range (ATR)
- HRMY 1.16
- ENLT 0.48
- MACD
- HRMY -0.60
- ENLT -0.04
- Stochastic Oscillator
- HRMY 6.60
- ENLT 68.79
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About ENLT Enlight Renewable Energy Ltd.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, which produces its revenue from the sale of the electricity that is produced through wind energy and solar energy in Europe.